Restricted accessResearch articleFirst published online 2011-03
Investigation on the Role of p53 Codon 72 Polymorphism and Interactions with Tobacco,Betel Quid,and Alcohol in Susceptibility to Cancers in a High-Risk Population from North East India
The association of TP53 codon 72 polymorphism with cancer susceptibility remains uncertain and varies with ethnicity. Northeast India represents a geographically, culturally, and ethnically isolated population. The area reports high rate of tobacco usage in a variety of ways of consumption, compared with the rest of Indian population. A total of 411 cancer patients (161 lung, 134 gastric, and 116 oral) and 282 normal controls from the ethnic population were analyzed for p53 codon 72 polymorphism by polymerase chain reaction–restriction fragment length polymorphism. No significant difference in genotypic distribution of p53 between cases and controls was observed. Results suggested betel quid chewing as a major risk factor for all the three cancers (odds ratio [OR] = 3.54, confidence interval [CI] = 2.01–6.25, p < 0.001; OR = 1.74, CI = 1.04–2.92, p = 0.03; and OR = 1.85, CI = 1.02–3.33, p = 0.04 for lung, gastric, and oral cancers, respectively). Tobacco smoking was associated with risk of lung and oral cancers (OR = 1.88, CI = 1.11–3.19, p = 0.01 and OR = 1.68, CI = 1.00–2.81, p = 0.04). Interactions between p53 genotypes and risk factors were analyzed to look for gene–environment interactions. Interaction of smoking and p53 genotype was significant only for oral cancer. Interactions of betel quid with p53 genotypes in lung cancer showed significant increase for all the three genotypes, indicating a major role of betel quid (OR = 5.90, CI = 1.67–20.81, p = 0.006; OR = 5.44, CI = 1.67–17.75, p = 0.005; and OR = 5.84, CI = 1.70–19.97, p = 0.005 for Arg/Arg, Arg/Pro, and Pro/Pro, respectively). In conclusion, high incidence of these cancers in northeast India might be an outcome of risk habits; further, tissue- and carcinogen-specific risk modification by p53 gene is probable.
Get full access to this article
View all access options for this article.
References
1.
Alpízar-AlpízarW., SierraR., CuencaP., UneC., MenaF., Pérez-PérezG.I.2005. Association of the p53 codon 72 polymorphism to gastric cancer risk in a hight risk population of Costa Rica. Rev Biol Trop, 53:317–324.
2.
BeckmanG., BirganderR., SjälanderA., SahaN., HolmbergP.A., KiveläA., BeckmanL.1994. Is p53 polymorphism maintained by natural selection?Hum Hered, 44:266–270.
3.
BergamaschiD., GascoM., HillerL., SullivanA., SyedN., TrigianteG.et al.2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3:387–403.
4.
BirganderR., SjalanderA., ZhouZ., FanC., BeckmanL., BeckmanG.1996. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered, 46:49–54.
5.
BomafeM., CeccarelliC., FarabegoliF., SantiniD., TaffurelliM.et al.2003. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res, 9:4860–4864.
6.
CáceresD.D., QuiñonesL.A., SchroederJ.C., GilL.D., IrarrázabalC.E.2009. Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung, 187:110–115.
7.
DokianakisD.N., SpandidosD.A.2000. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Mol Cell Biol Res Commun, 3:111–114.
8.
DrummondS.N., De MarcoL., Pordeus IdeA., BarbosaA.A., GomezR.S.2002. TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res, 22:3379–3381.
9.
FanR., WuM.T., MillerD., WainJ.C., KelseyK.T., WienckeJ.K., ChristianiD.C.2000. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 9:1037–1042.
10.
Fernández-RubioA., López-CimaM.F., González-ArriagaP., García-CastroL., PascualT., MarrónM.G., TardónA.2008. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer, 3:309–316.
11.
HamelN., BlackM.J., GhadirianP., FoulkesW.D.2000. No association between P53codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer, 82:757–759.
12.
HiyamaT., TanakaS., KitadaiY., ItoM., SumiiM.et al.2002. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori associated chronic gastritis. Int J Cancer, 100:304–308.
13.
HonmaH.N., De CapitaniE.M., PerroudM.W.Jr., BarbeiroA.S., ToroI.F., CostaD.B., LimaC.S., ZambonL.2008. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer, 61:152–162.
14.
JainN., SinghV., HedauS., KumarS., DagaM.K., DewanR., MurthyN.S., HusainS.A., DasB.C.2005. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest, 128:3999–4007.
15.
JinX., WuX., RothJ.A., AmosC.I., KingT.M.et al.1995. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis, 16:2205–2208.
16.
KatiyarS., ThelmaB.K., MurthyN.S., HedauS., JainN., GopalkrishnaV., HusainS.A., DasB.C.2003. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem, 252:117–124.
17.
KawajiriK., NakachiK., ImaiK., WatanabeJ., HayashiS.1993. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis, 14:1085–1089.
18.
KietthubthewS., SriplungH., AuW.W., IshidaT.2003. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev, 4:209–214.
19.
KimJ.M., LeeO.Y., LeeC.G., KwonS.J., KimK.S.et al.2007. p53 codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol, 50:292–298.
20.
KoY.C., HuatigY.L., LeeC.H., ChenM.J., LittL.M., TsaiC.C.1995. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med, 24:450–453.
21.
MatlashewskiG.J., TuckS., PimD., LambP., SchneiderJ., CrawfordL.V.1987. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol, 7:961–963.
22.
McWilliamsJ.E., EvansA.J., BeerT.M., AndersenP.E., CohenJ.I., EvertsE.C., HennerW.D.2000. Genetic polymorphisms in head and neck cancer risk. Head Neck, 22:609–617.
23.
MinaguchiT., KanamoriY., MatsushimaM., YoshikawaH., TaketaniY., NakamuraY.1998. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res, 58:4585–4586.
24.
MitraS., MisraC., SinghR.K., PandaC.K., RoychoudhuryS.2005. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol, 58:26–31.
25.
MojtahediZ., HaghshenasM.R., HosseiniS.V., FattahiM.J., GhaderiA.2010. p53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47:31–34.
26.
MudurG.2005. India has some of the highest cancer rates in the world. BMJ, 330:215.
27.
MurataM., TagawaM., KimuraM., KimuraH., WatanabeS., SaishoH.1996. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with king history. Carcinogenesis, 17:261–264.
28.
NagpalJ.K., PatnaikS., DasB.R.2002. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer, 97:649–653.
29.
NairU., BartschH., NairJ.2004. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis, 19:251–262.
30.
PapadakisE.D., SoulitzisN., SpandidosD.A.2002. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer, 87:1013–1018.
31.
PapadakisE.N., DokianakisD.N., SpandidosD.A.2000. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3:389–392.
32.
PietschE.C., HumbeyO., MurphyM.E.2006. Polymorphisms in the p53 pathway. Oncogene, 25:1602–1611.
33.
RogounovitchT.I., SaenkoV.A., AshizawaK., SedliarouI.A., NambaH.et al.2006. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep, 15:949–956.
34.
SalleyJ.J.1963. Smoking and oral cancer. J Dent Res, 42,Pt 2:328–339.
35.
ShenH., ZhengY., SturgisE.M., SpitzM.R., WeiQ.2002. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett, 183:123–130.
36.
SjalanderA., BirganderR., HallmansG., CajanderS., LennerP., AthlinL.et al.1996. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17:1313–1316.
37.
SjälanderA., BirganderR., KiveläA., BeckmanG.1995. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered, 45:144–149.
38.
SreejaL., SyamalaV., RaveendranP.B., SanthiS., MadhavanJ., AnkathilR.2008. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest, 26:41–46.
39.
StoreyA., ThomasM., KalitaA., HarwoodC., GardiolD., MantovaniF.et al.1998. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393:229–234.
40.
SulJ., YuG.P., LuQ.Y., LuM.L., SetiawanV.W.et al.2006. P53 codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett, 238:210–223.
41.
TandleA.T., SanghviV., SaranathD.2001. Determination of p53 genotypes in oral cancer patients from India. Br J Cancer, 84:739–742.
42.
ThomasM., KalitaA., LabrecqueS., PimD., BanksL., MatlashewskiG.1999. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19:1092–1100.
43.
To-FiguerasJ., GeneM., Gomez-CatalanJ., GalanC., FirvidaJ.et al.1996. Glutathione-S-transferase M 1 and codon 72 p53 polymorphisms in a northwestern mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 5:337–342.
44.
WangY.C., ChenC.Y., ChenS.K., ChangY.Y., LinP.1999a. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res, 5:129–134.
45.
WangY.C., LeeH.S., ChenS.K., ChangY.Y., ChenY.1999b. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer, 35:226–230.
46.
WenC.P., TsaiM.K., ChungW.S., HsuH.L., ChangY.C., ChanH.T., ChiangP.H., ChengT.Y., TsaiS.P.2010. Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking. Cancer Causes Control, 21:1427–1435.
47.
WestonA., PerrinL.S., ForresterK., HooverR.N., TrumpB.F., HarrisC.C., CaporasoN.E.1992. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev, 1:481–483.
48.
WuM.T., ChenM.C., WuD.C.2004. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett, 205:61–68.
49.
WuX., ZhaoH., AmosC.I., SheteS., MakanN., WaunK.et al.2002. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst, 94:681–690.
50.
WynderE.L., GrahamE.A., CroningerA.B.1953. Experimental production of carcinoma with cigarette tar. Cancer Res, 13:855–864.
51.
XiaoH., SinghS.V.2007. p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene–7,8-diol-9,10-epoxide in human lung cancer cells. Cell Cycle, 6:1753–1761.
52.
YiS.Y., LeeW.J.2006. A p53 genetic polymorphism of gastric cancer: Difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol, 12:6536–6539.
53.
ZhangZ.W., NewcombP., HollowoodA., FeakinsR., MoorghenM., StoreyA., FarthingM.J., AldersonD., HollyJ.2003. Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res, 9:2151–2156.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
